Savara Pharmaceuticals Gets $20M In Series C Funding

Austin-based Savara Pharmaceuticals announced this morning that it has raised $20M in a Series C funding round. Source of the funding was not disclosed. Savara said the funds go towards preparation for a Phase 3 clinical trail of its inhailed antibiotic, which is targeted at treating methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people with cystic fibrosis (CF). Savara, which is led by Rob Neville, has raised somewhere around $50M in funding. It's unclear if this new round includes the $10M in bridge funding announced by the company in October of 2014. More information »